Suppr超能文献

给药途径和剂量递增对肉鸡血浆及肠道中恩诺沙星和环丙沙星浓度的影响。

Effect of administration route and dose escalation on plasma and intestinal concentrations of enrofloxacin and ciprofloxacin in broiler chickens.

作者信息

Devreese Mathias, Antonissen Gunther, De Baere Siegrid, De Backer Patrick, Croubels Siska

机构信息

Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium.

出版信息

BMC Vet Res. 2014 Dec 2;10:289. doi: 10.1186/s12917-014-0289-1.

Abstract

BACKGROUND

The (mis)use of fluoroquinolones in the fowl industry has led to an alarming incidence of fluoroquinolone resistance in pathogenic as well as commensal bacteria. Next to simply reducing antimicrobial consumption, optimizing dosage regimens can be regarded as a suitable strategy to reduce antimicrobial resistance development without jeopardizing therapy efficacy and outcome. A first step in order to limit antimicrobial resistance is to assess the exposure of the intestinal microbiota to enrofloxacin after different treatment strategies. Therefore, a study was conducted in broiler chickens to assess the effect of route of administration (oral versus intramuscular) and dose escalation (10 and 50 mg/kg body weight) on plasma and intestinal concentrations of enrofloxacin and its main metabolite ciprofloxacin after treatment with enrofloxacin once daily for five consecutive days. Four different parts of the intestinal tract were sampled: ileum, cecum, colon and cloaca. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed to quantify both analytes in plasma and intestinal content. Sample preparation prior to LC-MS/MS analysis consisted of extraction with ethyl acetate. For intestinal content samples PBS buffer was added before extraction. The supernatant was evaporated to dryness and resuspended in water prior to analysis.

RESULTS

The results in plasma and intestinal content demonstrated that biotransformation of enro- to ciprofloxacin in broiler chickens is limited. In general, the intestinal microbiota in cecum and colon is exposed to significant levels of enrofloxacin after conventional treatment (21-130 μg/g). A clear increase of intestinal concentrations was demonstrated after administration of a five-fold higher dose (31-454 μg/g). After intramuscular administration, intestinal concentrations were comparable, except for the higher levels in cloaca due to the complete bioavailability and urinary excretion.

CONCLUSIONS

The intestinal microbiota is exposed to high levels of the antimicrobial, after oral as well as parenteral therapy. Furthermore, a dose and time dependent correlation was observed. The impact of the detected intestinal levels on resistance selection in the intestinal microbiota has to be further investigated.

摘要

背景

氟喹诺酮类药物在禽类养殖业中的(误)用已导致致病性和共生细菌中氟喹诺酮耐药性的发生率惊人。除了简单地减少抗菌药物的使用量外,优化给药方案可被视为一种在不影响治疗效果和结果的情况下减少抗菌药物耐药性产生的合适策略。为了限制抗菌药物耐药性,第一步是评估不同治疗策略后肠道微生物群对恩诺沙星的暴露情况。因此,在肉鸡中进行了一项研究,以评估给药途径(口服与肌肉注射)和剂量递增(10和50mg/kg体重)对连续五天每天一次用恩诺沙星治疗后血浆和肠道中恩诺沙星及其主要代谢物环丙沙星浓度的影响。对肠道的四个不同部位进行了采样:回肠、盲肠、结肠和泄殖腔。开发了一种液相色谱 - 串联质谱(LC-MS/MS)方法来定量血浆和肠道内容物中的两种分析物。LC-MS/MS分析前的样品制备包括用乙酸乙酯萃取。对于肠道内容物样品,在萃取前加入PBS缓冲液。将上清液蒸发至干并在分析前重新悬浮于水中。

结果

血浆和肠道内容物中的结果表明,肉鸡中恩诺沙星向环丙沙星的生物转化是有限的。一般来说,常规治疗后盲肠和结肠中的肠道微生物群会接触到显著水平的恩诺沙星(21 - 130μg/g)。给予五倍高剂量(31 - 454μg/g)后,肠道浓度明显增加。肌肉注射后,肠道浓度相当,除了泄殖腔中由于完全生物利用度和尿液排泄导致的较高水平。

结论

口服和肠胃外治疗后,肠道微生物群会接触到高水平的抗菌药物。此外,观察到剂量和时间依赖性相关性。检测到的肠道水平对肠道微生物群中耐药性选择的影响必须进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d654/4260181/afb5aa6f4574/12917_2014_289_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验